By Rightful Advice 
The ozempic lawsuit landscape continues to evolve in 2026 as thousands of plaintiffs seek compensation for alleged severe side effects linked to the popular glucagon-like peptide-1 (GLP-1) receptor agonist medication. Manufactured by Novo Nordisk, Ozempic (semaglutide) is approved for type 2 diabetes management and has gained widespread use for chronic weight management under related branding such as Wegovy. Similar claims target other GLP-1 drugs, including Eli Lilly’s Mounjaro and Zepbound.
As of May 2026, federal multidistrict litigation consolidates the majority of these cases, with no global settlement reached. This article provides a factual overview of the current status, drawing on court records, regulatory actions, and established legal procedures in product liability mass torts.
Background on Ozempic and the Emergence of Litigation
Ozempic received U.S. Food and Drug Administration (FDA) approval in 2017 for glycemic control in adults with type 2 diabetes. Its active ingredient, semaglutide, mimics the GLP-1 hormone to regulate blood sugar and suppress appetite. Post-approval, reports of gastrointestinal complications prompted increased scrutiny. In September 2023, the FDA updated the Ozempic label to include a warning for ileus, a condition involving impaired bowel motility.
Plaintiffs in the ozempic lawsuit allege that Novo Nordisk failed to provide adequate warnings about risks such as gastroparesis (stomach paralysis), ileus, intestinal obstruction, and, more recently, non-arteritic anterior ischemic optic neuropathy (NAION), a form of sudden vision loss. These claims center on products liability theories, primarily failure to warn and design defect, under common law principles applied across jurisdictions.
The litigation gained momentum in 2023 with the first gastroparesis-related filings. By early 2024, the Judicial Panel on Multidistrict Litigation (JPML) centralized federal cases to promote efficiency, consistent with 28 U.S.C. § 1407 procedures for handling complex, factually related actions.
Current Status of the Ozempic Multidistrict Litigation (MDL 3094)
The primary federal proceeding is In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, designated MDL No. 3094 and assigned to U.S. District Judge Karen Spencer Marston in the Eastern District of Pennsylvania.
As of May 1, 2026, JPML statistics report 3,636 pending actions in MDL 3094, with total actions filed reaching approximately 3,670. The docket continues to grow, reflecting ongoing direct filings and tag-along petitions.
This MDL addresses gastrointestinal injuries, including gastroparesis, ileus, and bowel obstruction. The court conducts monthly status conferences and has issued multiple case management orders addressing plaintiff fact sheets, discovery protocols, and scheduling for cross-cutting issues such as general causation. Recent orders, including Amended Case Management Order No. 12 on plaintiff fact sheets and scheduling updates for 2026 conferences, underscore the pretrial focus.
Bellwether trial selection remains underway. These representative cases, chosen through a process involving input from plaintiffs’ and defendants’ leadership, will undergo full discovery and trial preparation to test liability and damages theories. Legal analysts anticipate the first bellwether trials in late 2026 or early 2027, a standard timeline in MDLs that allows parties to evaluate evidence strength before broader negotiations.
A separate but related MDL, No. 3163 (In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation), handles vision loss claims. Established in December 2025, it also sits before Judge Marston and reported 86 pending cases as of May 1, 2026. Pretrial proceedings include planning for a Science Day in June 2026 to educate the court on the underlying scientific issues.
Parallel state court actions proceed independently in venues such as New Jersey, where consolidated proceedings address both gastrointestinal and NAION claims on separate tracks.
Allegations and Injuries in Ozempic Lawsuits
Central to the ozempic lawsuit are allegations that manufacturers knew or should have known about elevated risks based on clinical data and post-marketing surveillance yet marketed the drugs without sufficient warnings. Plaintiffs report severe, sometimes permanent conditions requiring hospitalization, feeding tubes, surgical intervention, or resulting in malnutrition and vision impairment.
Courts require plaintiffs to establish specific causation through medical evidence. For gastroparesis claims, a ruling in the MDL has emphasized the need for confirmatory testing, such as gastric emptying studies, rather than reliance solely on clinical observations. This evidentiary threshold affects case viability but aligns with standard products liability requirements for proving injury and causation.
Defendants maintain that labels adequately disclose known risks, including common gastrointestinal effects, and that these events remain rare. Novo Nordisk and Eli Lilly contest general causation, arguing studies show associations but not definitive proof of causation at the population level.
Settlement Status and Outlook
No global settlement has been announced in either MDL as of May 2026. Individual cases have not resulted in publicly disclosed resolutions tied to the coordinated proceedings.
In products liability MDLs, settlements typically follow bellwether outcomes, which provide benchmarks for valuation. Projections from plaintiffs’ counsel, based on comparable mass tort resolutions involving gastrointestinal injuries or vision loss, remain speculative and range widely depending on injury severity, medical documentation, and jury reception. Factors influencing potential resolution include the strength of scientific evidence presented at Daubert hearings, which assess expert testimony admissibility under Federal Rule of Evidence 702.
The litigation remains in the discovery and case-selection phase. Global resolution, if it occurs, would likely follow bellwether trials and extensive negotiations facilitated by the court or private mediators. Parties may also pursue individual settlements or explore alternative dispute resolution mechanisms as the docket matures.
Who May Be Affected and Next Steps in the Legal Process
Individuals who used Ozempic, Wegovy, or related GLP-1 medications and subsequently experienced documented gastroparesis, ileus, intestinal obstruction, NAION, or related complications may have claims eligible for inclusion in the MDL or state proceedings. Qualification depends on medical records establishing a temporal relationship and diagnosis, consistent with tort principles of proximate cause.
The legal process for each plaintiff involves filing a complaint, completing a plaintiff fact sheet with detailed medical and usage history, and participating in discovery. Courts encourage early evaluation of claims to streamline dockets.
This article is for informational purposes only and does not constitute legal advice. Readers should consult qualified counsel for personalized evaluation of their circumstances. Lawsuit eligibility, statutes of limitations, and outcomes vary by jurisdiction and individual facts. The information reflects publicly available court data and regulatory records as of May 2026 and may change with new developments.
Ongoing monitoring of JPML reports, Eastern District of Pennsylvania dockets, and FDA communications remains essential for those tracking the ozempic lawsuit and related GLP-1 litigation. The proceedings illustrate broader challenges in balancing pharmaceutical innovation with post-market safety obligations under federal and state regulatory frameworks.
You may also like: Blingle Lawsuit Updates 2026: Franchise Litigation & Settlement Status